Displaying drugs 10251 - 10275 of 12418 in total
Eperisone
Eperisone is an antispasmodic drug which relaxes both skeletal muscles and vascular smooth muscles, and demonstrates a variety of effects such as reduction of myotonia, improvement of circulation, and suppression of the pain reflex. It is not approved for use in the United States, but is available in other countries...
Investigational
Matched Description: … effects such as reduction of myotonia, improvement of circulation, and suppression of the pain reflex ... antispasmodic drug which relaxes both skeletal muscles and vascular smooth muscles, and demonstrates a variety of …
Adlinacogene civaparvovec
Adlinacogene civaparvovec is an investigational in vivo genome editing therapeutic product. It uses proprietary zinc finger nuclease (ZFN) genome editing to insert into the DNA of liver cells a copy of the F9 gene, which controls the production of Factor IX. Developed by Sangamo Therapeutics Inc., it is being investigated...
Experimental
Matched Description: … copy of the F9 gene, which controls the production of Factor IX. ... It uses proprietary zinc finger nuclease (ZFN) genome editing to insert into the DNA of liver cells a ... [L46711] Developed by Sangamo Therapeutics Inc., it is being investigated for the treatment of hemophilia …
CAD106
CAD106 is an immunotherapeutic product in development for the treatment of Alzheimer's disease. It is designed to induce antibodies against the beta-amyloid-protein that inhibit the formation of plaques in the brain of Alzheimer's disease patients.
Investigational
Matched Description: … in the brain of Alzheimer's disease patients. ... CAD106 is an immunotherapeutic product in development for the treatment of Alzheimer's disease. ... It is designed to induce antibodies against the beta-amyloid-protein that inhibit the formation of plaques …
Egaptivon pegol
Egaptivon pegol, formerly known as ARC1779, is a therapeutic aptamer antagonist of the A1 domain of von Willebrand Factor (vWF), the ligand for receptor glycoprotein 1b on platelets. Egaptivon pegol is being investigated for the treatment of thrombotic thrombocytopenic purpura and acute coronary syndromes.[A3290, A259053] Egaptivon pegol is a therapeutic...
Investigational
Matched Description: … Egaptivon pegol, formerly known as ARC1779, is a therapeutic aptamer antagonist of the A1 domain of von ... , and aggregation under the high shear conditions of coronary arterial stenosis and plaque rupture. ... Egaptivon pegol is being investigated for the treatment of thrombotic thrombocytopenic purpura and acute …
DTS-201
DTS-201 is a prodrug of doxorubicin, a widely used anti-cancer drug that Diatos intends to develop for the treatment of various solid tumors. It is activated in the tumor environment.
DTS-201 may be suitable for the treatment of many types of solid tumors, including tumors sensitive to doxorubicin and potentially...
Investigational
Matched Description: … DTS-201 may be suitable for the treatment of many types of solid tumors, including tumors sensitive to ... the treatment of various solid tumors. ... DTS-201 is a prodrug of doxorubicin, a widely used anti-cancer drug that Diatos intends to develop for …
Molybdenum cofactor
Absence of molybdenum cofactor leads to accumulation of toxic levels of sulphite and neurological damage usually leading to death within months of birth, due to the lack of active sulfite oxidase.
Experimental
Matched Description: … Absence of molybdenum cofactor leads to accumulation of toxic levels of sulphite and neurological damage ... usually leading to death within months of birth, due to the lack of active sulfite oxidase. …
SYNB1891
SYNB1891 is a live, modified strain of the probiotic Escherichia coli Nissle engineered to produce cyclic di-AMP (CDA), a stimulator of the STING (STimulator of INterferon Genes) pathway. SYNB1891 is under investigation in clinical trial NCT04167137 (Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult...
Investigational
Matched Description: … cyclic di-AMP (CDA), a stimulator of the STING (STimulator of INterferon Genes) pathway. ... SYNB1891 is a live, modified strain of the probiotic _Escherichia coli_ Nissle engineered to produce ... [A256733] SYNB1891 is under investigation in clinical trial NCT04167137 (Safety and Tolerability of SYNB1891 …
Chlorproguanil
Chlorproguanil has been used in trials studying the treatment of MALARIA. It is a dichloro-derivative of chloroguanide.
Investigational
Matched Description: … It is a dichloro-derivative of chloroguanide. ... Chlorproguanil has been used in trials studying the treatment of MALARIA. …
TOL2
TOL2 is a modified form of the acetylcholine receptor being investigated for the treatment of myasthenia gravis.
Investigational
Matched Description: … TOL2 is a modified form of the acetylcholine receptor being investigated for the treatment of myasthenia …
Cenderitide
Cenderitide is under investigation for the treatment of ST Elevation (STEMI) Myocardial Infarction of Anterior Wall.
Investigational
Matched Description: … Cenderitide is under investigation for the treatment of ST Elevation (STEMI) Myocardial Infarction of …
Suvratoxumab
Suvratoxumab is under investigation in clinical trial NCT02296320 (Study of the Efficacy and Safety of MEDI4893).
Investigational
Matched Description: … Suvratoxumab is under investigation in clinical trial NCT02296320 (Study of the Efficacy and Safety of …
DS-2325a
DS-2325a is an inhibitor of kallikrein 5 under development for the treatment of Netherton Syndrome.
Investigational
Matched Description: … DS-2325a is an inhibitor of kallikrein 5 under development for the treatment of Netherton Syndrome. …
AVI-4557
AVI-4557 is an oral antisense compound that selectively inhibits the metabolic enzyme cytochrome P450 3A4 (CYP), a liver enzyme responsible for the metabolism or breakdown of approximately half of currently marketed drugs. Studies indicate that AVI-4557 can successfully reduce the rate of metabolism for certain drugs, therefore allowing greater and...
Investigational
Matched Description: … approximately half of currently marketed drugs. ... anxiety, cancer, and a number of other serious conditions. ... metabolic enzyme cytochrome P450 3A4 (CYP), a liver enzyme responsible for the metabolism or breakdown of …
Centanafadine
Centanafadine is under investigation in clinical trial NCT02827513 (A Phase 1 Study to Investigate the Safety, Tolerance, Food Effect, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of Extended Release Formulations of Centanafadine (CTN) in Young Healthy Subjects).
Investigational
Matched Description: … Single and Multiple Doses of Extended Release Formulations of Centanafadine (CTN) in Young Healthy Subjects ... Phase 1 Study to Investigate the Safety, Tolerance, Food Effect, Pharmacokinetics and Pharmacodynamics of …
XmAb 2513
XmAb 2513 is a humanized monoclonal antibody that targets the antigen CD30, a molecule expressed on the surface of a number of tumor cell types. It has been investigated for the treatment of hodgkin’s lymphoma.
Investigational
Matched Description: … a number of tumor cell types. ... It has been investigated for the treatment of hodgkin’s lymphoma. ... a humanized monoclonal antibody that targets the antigen CD30, a molecule expressed on the surface of …
SYNB1020
SYNB1020 is an engineered strain of Escherichia coli Nissle 1917 developed by Synlogic Inc. It was initially designed to convert ammonia to L-arginine and granted orphan designation by the FDA for the treatment of urea cycle disorders in August 2016; however, the manufacturer discontinued further development of SYNB1020 to treat...
Investigational
Matched Description: … SYNB1020 to treat hyperammonemia due to a lack of evidence of ammonia-lowering activities by SYNB1020 ... SYNB1020 is an engineered strain of _Escherichia coli_ Nissle 1917 developed by Synlogic Inc. ... convert ammonia to L-arginine [A258838] and granted orphan designation by the FDA for the treatment of …
PN0621
PN0621 is an anti-TNF, domain antibody (dAb) based therapeutic. It targets tumour necrosis factor (TNF) to treat auto-immune inflammatory diseases such as rheumatoid arthritis. It is being developed by Peptech.
Investigational
Fibrinolysin
Fibrinolysin consists of two polypeptide chains, one light and one heavy, linked by a disulfide bond. The light chain has a molecular weight of approximately 27,000 Da and contains the active center of Fibrinolysin; the heavy chain has a molecular weight of approximately 57,000 Da. Fibrinolysin is used as a...
Investigational
Matched Description: … The light chain has a molecular weight of approximately 27,000 Da and contains the active center of Fibrinolysin ... ; the heavy chain has a molecular weight of approximately 57,000 Da. ... Fibrinolysin consists of two polypeptide chains, one light and one heavy, linked by a disulfide bond. …
Nifekalant
Nifekalant is under investigation in clinical trial NCT03855826 (Evaluation of the Efficacy and Safety of Nifekalant Hydrochloride (NIF) Injection).
Investigational
Matched Description: … of Nifekalant Hydrochloride (NIF) Injection). ... Nifekalant is under investigation in clinical trial NCT03855826 (Evaluation of the Efficacy and Safety …
Menaquinone 6
Menaquinone 6 is under investigation in clinical trial NCT01194778 (Comparison of Efficacy of Different Dosages Vitamin K2).
Investigational
Matched Description: … Menaquinone 6 is under investigation in clinical trial NCT01194778 (Comparison of Efficacy of Different …
Gatralimab
Gatralimab is under investigation in clinical trial NCT02389452 (Study of Safety and Efficacy of 6 Ml Synvisc-one (Hylan G-F 20) in Indian Patients With Symptomatic Osteoarthritis of Knee(s) After Initial and Repeat Treatment).
Investigational
Matched Description: … Gatralimab is under investigation in clinical trial NCT02389452 (Study of Safety and Efficacy of 6 Ml ... Synvisc-one (Hylan G-F 20) in Indian Patients With Symptomatic Osteoarthritis of Knee(s) After Initial …
BLX-883
BLX-883 is a form of alfa interferon developed by Biolex for the treatment of hepatitis viral C. Alfa interferon is used in the treatment of hepatitis C, hepatitis B, and multiple cancers and its worldwide sales currently exceed $3 billion.
Investigational
Matched Description: … BLX-883 is a form of alfa interferon developed by Biolex for the treatment of hepatitis viral C. ... Alfa interferon is used in the treatment of hepatitis C, hepatitis B, and multiple cancers and its worldwide …
Baicalein
Baicalein is under investigation in clinical trial NCT03830684 (A Randomized, Double-blind, Placebo-controlled, Multicenter and Phase ⅡA Clinical Trial for the Effectiveness and Safety of Baicalein Tablets in the Treatment of Improve Other Aspects of Healthy Adult With Influenza Fever).
Investigational
Matched Description: … Baicalein Tablets in the Treatment of Improve Other Aspects of Healthy Adult With Influenza Fever). ... Double-blind, Placebo-controlled, Multicenter and Phase ⅡA Clinical Trial for the Effectiveness and Safety of …
Varlitinib
Varlitinib is an oral, selective, reversible, small molecule tyrosine kinase inhibitor of both ErbB-2 (Her-2/neu) and EGFR. Over-expression of ErbB-2 and EGFR receptors in tumors is predictive of poor prognosis in cancer patients. Varlitinib has shown significant anti-tumor activity in preclinical models of human breast, lung, and epidermal carcinoma tumors.
Investigational
Matched Description: … Over-expression of ErbB-2 and EGFR receptors in tumors is predictive of poor prognosis in cancer patients ... Varlitinib is an oral, selective, reversible, small molecule tyrosine kinase inhibitor of both ErbB-2 ... Varlitinib has shown significant anti-tumor activity in preclinical models of human breast, lung, and …
Dianexin
Dianexin is under investigation in clinical trial NCT00615966 (Phase 2 Study of the Safety of Diannexin in Kidney Transplant Recipients).
Investigational
Matched Description: … Dianexin is under investigation in clinical trial NCT00615966 (Phase 2 Study of the Safety of Diannexin …
Displaying drugs 10251 - 10275 of 12418 in total